Albireo Pharma, Inc. (ALBO): Price and Financial Metrics


Albireo Pharma, Inc. (ALBO): $27.30

1.62 (+6.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALBO POWR Grades


  • Sentiment is the dimension where ALBO ranks best; there it ranks ahead of 73.4% of US stocks.
  • ALBO's strongest trending metric is Value; it's been moving up over the last 170 days.
  • ALBO's current lowest rank is in the Momentum metric (where it is better than 9.24% of US stocks).

ALBO Stock Summary

  • Albireo Pharma Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 10.02% of US listed stocks.
  • For ALBO, its debt to operating expenses ratio is greater than that reported by only 11.8% of US equities we're observing.
  • With a price/sales ratio of 48.85, Albireo Pharma Inc has a higher such ratio than 96.13% of stocks in our set.
  • Stocks that are quantitatively similar to ALBO, based on their financial statements, market capitalization, and price volatility, are FOLD, DYAI, KOPN, EXEL, and PDEX.
  • Visit ALBO's SEC page to see the company's official filings. To visit the company's web site, go to www.albireopharma.com.

ALBO Valuation Summary

  • ALBO's price/sales ratio is 63.7; this is 461.23% higher than that of the median Healthcare stock.
  • Over the past 173 months, ALBO's price/sales ratio has gone NA NA.
  • ALBO's price/sales ratio has moved NA NA over the prior 173 months.

Below are key valuation metrics over time for ALBO.

Stock Date P/S P/B P/E EV/EBIT
ALBO 2021-08-31 63.7 5.2 -4.3 -3.4
ALBO 2021-08-30 63.1 5.1 -4.3 -3.4
ALBO 2021-08-27 62.1 5.1 -4.2 -3.3
ALBO 2021-08-26 59.7 4.9 -4.1 -3.1
ALBO 2021-08-25 60.6 4.9 -4.1 -3.2
ALBO 2021-08-24 62.3 5.1 -4.2 -3.3

ALBO Growth Metrics

    Its 4 year price growth rate is now at 109.22%.
  • The 5 year net cashflow from operations growth rate now stands at -274.67%.
  • The year over year revenue growth rate now stands at -17.8%.
ALBO's revenue has moved down $1,966,000 over the prior 33 months.

The table below shows ALBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 10.774 -121.863 -47.867
2021-06-30 9.241 -120.352 -135.696
2021-03-31 8.725 -111.949 -119.878
2020-12-31 8.308 -101.029 -107.633
2020-09-30 12.023 -85.234 -90.356
2020-06-30 11.277 -73.268 -81.523

ALBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALBO has a Quality Grade of D, ranking ahead of 12.41% of graded US stocks.
  • ALBO's asset turnover comes in at 0.035 -- ranking 346th of 680 Pharmaceutical Products stocks.
  • LCI, MBIO, and XNCR are the stocks whose asset turnover ratios are most correlated with ALBO.

The table below shows ALBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.035 1 -72.830
2021-03-31 0.034 1 -28.871
2020-12-31 0.035 1 -35.203
2020-09-30 0.057 1 -49.355
2020-06-30 0.064 1 -125.682
2020-03-31 0.061 1 30.641

ALBO Price Target

For more insight on analysts targets of ALBO, see our ALBO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.86 Average Broker Recommendation 1.25 (Strong Buy)

ALBO Stock Price Chart Interactive Chart >

Price chart for ALBO

ALBO Price/Volume Stats

Current price $27.30 52-week high $43.41
Prev. close $25.68 52-week low $20.30
Day low $24.94 Volume 252,700
Day high $27.39 Avg. volume 238,895
50-day MA $24.36 Dividend yield N/A
200-day MA $29.44 Market Cap 526.32M

Albireo Pharma, Inc. (ALBO) Company Bio


Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.


ALBO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALBO Latest Social Stream


Loading social stream, please wait...

View Full ALBO Social Stream

Latest ALBO News From Around the Web

Below are the latest news stories about Albireo Pharma Inc that investors may wish to consider to help them evaluate ALBO as an investment opportunity.

When Can We Expect A Profit From Albireo Pharma, Inc. (NASDAQ:ALBO)?

We feel now is a pretty good time to analyse Albireo Pharma, Inc.'s ( NASDAQ:ALBO ) business as it appears the company...

Yahoo | January 19, 2022

Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | January 12, 2022

Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

Yahoo | January 12, 2022

Albireo Pharma (ALBO) Receives a Buy from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Albireo Pharma (ALBO – Research Report), with a price target of $80.00. The company's shares closed last Thursday at $25.86. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.6% and a 38.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $79.00, a 217.1% upside from current levels.

Brian Anderson on TipRanks | January 7, 2022

Analysts’ Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma (ALBO – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Albireo Pharma (ALBO) Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma today and set a price target of $84.00. The company's shares closed last Wednesday at $24.31. According to TipRanks.

Brian Anderson on TipRanks | January 6, 2022

Read More 'ALBO' Stories Here

ALBO Price Returns

1-mo 15.53%
3-mo -6.57%
6-mo -5.57%
1-year -25.55%
3-year 12.44%
5-year 37.81%
YTD 17.22%
2021 -37.91%
2020 47.56%
2019 3.63%
2018 -4.18%
2017 44.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8286 seconds.